The ophthalmologic management of acute Stevens-Johnson syndrome

Ocular Surface

Volumn 6, Issue 2, 2008, Pages 87-95

  Gregory, Darren G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Amniotic membrane; Conjunctivitis; Dry eye; Inflammation; Stevens Johnson syndrome; Symblepharon; Toxic epidermal necrolysis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; FAS LIGAND; FIBRIN GLUE; IMMUNOGLOBULIN; MOXIFLOXACIN;

AMNION; APOPTOSIS; ARTICLE; CONJUNCTIVITIS; DRUG EFFICACY; DRUG TISSUE LEVEL; DRY EYE; EVENING DOSAGE; EYE DISEASE; EYE PROTECTIVE DEVICE; GENETIC SUSCEPTIBILITY; HUMAN; MORNING DOSAGE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHOTOPHOBIA; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROGNOSIS; SINGLE DRUG DOSE; SKIN INFECTION; STEVENS JOHNSON SYNDROME; SURGICAL TECHNIQUE; SYMBLEPHARON; SYSTEMIC THERAPY; THERAPY EFFECT; TISSUE TRANSPLANTATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TRICHIASIS; VISUAL IMPAIRMENT;

EID: 46149113498     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70273-2     Document Type: Article

References (45)

1. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42
2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7
3. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4
4. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162:1515-20
5. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16
6. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123:1171-3
7. Dietrich A, Kawakubo Y, Rzany B, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995;4:313-6
8. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-33
9. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-55
10. Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Opthalmology 1995;102:1669-76
11. Chang Y, Huang F, Tseng S, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-9
12. De Rojas MV, Dart JK, Saw VP The natural history of Stevens-Johnson syndrome: patterns of chronic ocular disease and the role systemic immunosuppressive therapy. Br J Ophthalmol 2007;91:1048-53
13. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Eye 2005;19:846-53.
14. Haber J, Hopman W, Gomez M, Cartotto R: Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005;26:33-41
15. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005;112:904-12
16. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002;138:1019-24
17. Kelemen JJ, Cioffi WG, McManus WF, et al. Burn Center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180: 273-8
18. Murphy JT, Purdue GF Hunt JL. Toxic epidermal necrolysis. Burn Care Rehabil 1997;18:417-20
19. McGee T, Munster A. Toxic epidermal necrolysis syndrome mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102:1018-22
20. Mittman N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006;7:359-68
21. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9
22. Schneck J, Fagot J, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40
23. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153:241-53
24. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma 2000;48:473-8
25. Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007;49:659-62
26. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50:S32-45
27. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxaci, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 2005; 123:1282-3
28. Scheinfeld N. A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. J Drugs Dermatol 2007;6:352-5
29. Rosenthal P, Cotter J. The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am 2003;16:89-93
30. John T, Foulks GN, John ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 2002;109:351-60
31. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology 2006; 113:126-132
32. Muquit M, Ellingham R, Daniel C. Technique of amniotic membrane transplant dressing in the management of acute Stevens-Johnson syndrome. Br J Ophthalmol 2007;91:1536
33. Tandon A, Cackett P, Mulvihill A, Fleck B. Amniotic membrane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis. J AAPOS 2007; 11: 612-3
34. Dua HS, Gomes JAP, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol 2004;49:51-77
35. Gomes JA, Romano A, Santos MS, Dua HS. Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol 2005;16:233-240
36. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surf 2004;2:177-87
37. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Opthalmology 2000;107:980-90.
38. Tamhane A, Vajpayee RB, Biswas N, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. Opthalmology 2005; 112:1963-1969
39. Solomon A, Meller D, Prabhasawat P, et al. Amniotic membrane grafts for nontraumatic corneal perforations, descemeroceles, and deep ulcers. Ophthalmology 2002;109:694-703
40. Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology 1999;106:1504-11
41. Bouchard CS, John I Ammniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocul Surf 2004;2:177-87
42. Sekiyama E, Nakamura T, Kurihara E, Cooper LJ, Fullwood NJ, Takaoka M, Hamuro J, Kinoshita S. Novel sutureless transplantation of bioadhesive-coated, freeze-dried amniotic membrane for ocular surface reconstruction. Invest Ophthalmol Vis Sci 2007;48:1528-34.
43. Uhlig CE, Busse H, Groppe M. Use of fibrin glue in fixation of amniotic membranes in sterile corneal ulceration. Am J Ophthalmol 2006;142:189-91
44. Szurman P, Warga M, Grisanti S, et al. Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model. Cornea 2006;25:460-6
45. Hick S, Demers PE, Brunette I; et al. Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: a review of 33 cases. Cornea 2005;24:369-77